Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640664 · ClinicalTrials.gov registry record · Phase 3
Rainbow Extension Study
A Phase 3 study of Retinopathy of Prematurity (ROP), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT02640664 is a Phase 3 study of Retinopathy of Prematurity (ROP) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 180 participants, below the 2,499-participant average among 3 other Retinopathy of Prematurity (ROP) trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02640664, a Phase 3 study of Retinopathy of Prematurity (ROP), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (20)
Other
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Bruges
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Zagreb
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Koebenhavn Ø
- Novartis Investigative Site - Alexandria
- Novartis Investigative Site - Tallinn
California
- Novartis Investigative Site - Sacramento
Colorado
- Novartis Investigative Site - Aurora
Illinois
- Novartis Investigative Site - Chicago
Kentucky
- Novartis Investigative Site - Louisville
Maryland
- Novartis Investigative Site - Baltimore
Michigan
- Novartis Investigative Site - Ann Arbor
New York
- Novartis Investigative Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02640664
The ClinicalTrials.gov registry entry for NCT02640664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,499-participant average among 3 other Retinopathy of Prematurity (ROP) trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinopathy of Prematurity (ROP) appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT02640664 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02640664 about?
NCT02640664 is a clinical study titled "Rainbow Extension Study". The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)
What is the current status of trial NCT02640664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2016-06-16. Estimated completion is 2022-04-21.
What conditions does trial NCT02640664 study?
This clinical trial studies the following conditions: Retinopathy of Prematurity (ROP).
What interventions are being tested in trial NCT02640664?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT02640664?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02640664 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinopathy of Prematurity (ROP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.